文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

自身免疫性胃炎中质子泵抑制剂使用与胃神经内分泌肿瘤的关联:意大利自身免疫性胃炎网络真实世界倾向评分匹配研究

Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real-World Propensity Score-Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup.
PubMed 文献 · Aliment Pharmacol Ther · 2026-09-06

本研究基于TriNetX全球协作网络开展回顾性倾向评分匹配队列研究,纳入153,687例自身免疫性胃炎(AIG)患者,1:1匹配后每组40,489例。PPI暴露组胃神经内分泌肿瘤(gNENs)发生率为0.89%,未暴露组为0.60%,PPI暴露与gNENs发生风险升高相关(RR 1.49,95%CI 1.27-1.76;HR 1.44,95%CI 1.22-1.70;log-rank p<0.001)。PPI暴露还与高胃泌素血症、肠化生和胃息肉发生增加相关。

要点

  • AIG患者中PPI暴露与gNENs发生风险升高相关(RR 1.49,95%CI 1.27-1.76)。
  • PPI暴露还与高胃泌素血症、肠化生和胃息肉发生增加相关。
  • gNENs绝对风险仍较低,但支持AIG患者审慎长期使用PPI并加强内镜监测。

核心结论

  • 在AIG患者中,PPI暴露与总体及新发gNENs发生增加相关,并与胃黏膜改变(高胃泌素血症、肠化生、胃息肉) consistently相关。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,使用TriNetX全球协作网络数据库,纳入153,687例AIG患者,1:1匹配后每组40,489例。

主要发现

  • 匹配后,无PPI暴露组gNENs发生241例(0.60%),PPI暴露组360例(0.89%)。
  • PPI暴露与gNENs发生风险升高相关(RR 1.49,95%CI 1.27-1.76;HR 1.44,95%CI 1.22-1.70;log-rank p<0.001)。
  • 排除既往gNENs后关联持续(RR 1.61,95%CI 1.26-2.06;HR 1.52,95%CI 1.19-1.95)。
  • PPI暴露与高胃泌素血症(HR 1.17,95%CI 1.00-1.37)、肠化生(HR 1.53,95%CI 1.36-1.71)和胃息肉(HR 2.48,95%CI 2.25-2.73)发生增加相关。
  • 随访期间未发现胃腺癌。

临床怎么用

  • AIG患者长期使用PPI应审慎评估适应证。
  • AIG患者应重视适当的内镜监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Autoimmune gastritis (AIG) is characterized by chronic hypergastrinemia and is associated with an increased risk of gastric neuroendocrine neoplasms (gNENs). Because proton pump inhibitors (PPIs) further increase gastrin secretion, concerns have been raised regarding a potential additive effect on gastric neoplastic risk. This study aimed to evaluate the association between PPI exposure and gNEN occurrence in patients with AIG using a large real-world database. METHODS: We conducted a retrospective propensity score-matched cohort study using the TriNetX Global Collaborative Network. Patients with AIG were identified using diagnostic codes for chronic atrophic gastritis or pernicious anaemia, excluding Helicobacter pylori infection, gastric cancer, multiple endocrine neoplasia or other competing gastric conditions. Two cohorts were defined: patients with AIG receiving PPIs and patients without PPI exposure. The primary outcome was the overall occurrence of gNENs. A prespecified secondary analysis excluded patients with gNENs diagnosed before the index date to evaluate incident tumours. Secondary outcomes included hypergastrinemia, intestinal metaplasia and gastric polyps. RESULTS: A total of 153,687 patients with AIG were identified. After 1:1 propensity score matching, 40,489 patients were included in each cohort. After propensity score matching, gNENs were recorded in 241 patients (0.60%) without PPI exposure and 360 patients (0.89%) receiving PPIs. PPI exposure was associated with a significantly higher occurrence of gNENs (risk ratio [RR] 1.49, 95% CI 1.27-1.76), which was confirmed by time-to-event analysis (hazard ratio [HR] 1.44, 95% CI 1.22-1.70; log-rank p < 0.001). The association persisted after exclusion of patients with pre-existing gNENs (RR 1.61, 95% CI 1.26-2.06; HR 1.52, 95% CI 1.19-1.95). PPI exposure was also associated with higher occurrences of hypergastrinemia (HR 1.17, 95% CI 1.00-1.37), intestinal metaplasia (HR 1.53, 95% CI 1.36-1.71) and gastric polyps (HR 2.48, 95% CI 2.25-2.73). No gastric adenocarcinomas were identified during follow-up. CONCLUSIONS: In this large real-world propensity score-matched study, PPI exposure was associated with a greater occurrence of both overall and incident gNENs in patients with AIG. PPI use was also consistently associated with gastric mucosal alterations, including hypergastrinemia, intestinal metaplasia and gastric polyps. Although the absolute risk of gNENs remained low, these findings support judicious long-term PPI prescribing in patients with AIG and reinforce the importance of appropriate endoscopic surveillance in this high-risk population.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Massironi S, Lenti MV, Lahner E, et al. Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real-World Propensity Score-Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup. Aliment Pharmacol Ther. 2026. PMID: 42701999. doi:10.1111/apt.70954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。